Development and Validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 3.0.

Objective: To modify the Pediatric Medical Complexity Algorithm (PMCA) to include both International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9/10-CM) codes for classifying children with chronic disease (CD) by level of medical complexity and to assess the sensitivity and specificity of the new PMCA version 3.0 for correctly identifying level of medical complexity.

Methods: To create version 3.

Trust and distrust between patient and doctor.

To trust someone is to have expectations of their behaviour; distrust often involves disappointed expectations. But healthy trust and distrust require a good understanding of which expectations are reasonable, and which are not. In this paper, I discuss the limits of trustworthiness by drawing on recent studies of trust in the context of defensive medicine, biobanking and cardiopulmonary resuscitation decisions.

Weight loss in obese African American and Caucasian adolescents: secondary analysis of a randomized clinical trial of behavioral therapy plus sibutramine.

Background: Obesity, a major risk factor for cardiovascular disease, is more prevalent in African American adolescents than in their Caucasian counterparts. Effective weight loss treatment options are required to aid in the reduction of this health disparity. The purpose of this study, a secondary analysis of data collected as part of a double-blind, randomized clinical trial of behavioral and pharmacologic weight loss, was to examine and compare changes in weight loss and cardiometabolic risk factors in African American and Caucasian adolescents.

Dynamics of the upper 50-kDa domain of myosin V examined with fluorescence resonance energy transfer.

The upper 50-kDa region of myosin may be critical for coupling between the nucleotide- and actin-binding regions. We introduced a tetracysteine motif in the upper 50-kDa domain (residues 292-297) of myosin V containing a single IQ domain (MV 1IQ), allowing us to label this site with the fluorescein biarscenical hairpin-binding dye (FlAsH) (MV 1IQ FlAsH). The enzymatic properties of MV 1IQ FlAsH were similar to those of unlabeled MV 1IQ except for a 3-fold reduced ADP-release rate.